Ascendis PharmaASND
ASND
About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Employees: 1,017
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
31% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 65
1.92% more ownership
Funds ownership: 103.93% [Q3] → 105.84% (+1.92%) [Q4]
3% less funds holding
Funds holding: 218 [Q3] → 211 (-7) [Q4]
6% less capital invested
Capital invested by funds: $9.31B [Q3] → $8.78B (-$537M) [Q4]
10% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 39
18% less funds holding in top 10
Funds holding in top 10: 17 [Q3] → 14 (-3) [Q4]
64% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $32.7M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$200
21%
upside
Avg. target
$218
32%
upside
High target
$260
58%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target | 24%upside $205 | Outperform Initiated | 16 Apr 2025 |
JP Morgan Jessica Fye 53% 1-year accuracy 19 / 36 met price target | 21%upside $200 | Overweight Maintained | 18 Mar 2025 |
Cantor Fitzgerald Li Watsek 24% 1-year accuracy 9 / 38 met price target | 21%upside $200 | Overweight Maintained | 25 Feb 2025 |
Evercore ISI Group Josh Schimmer 20% 1-year accuracy 11 / 54 met price target | 58%upside $260 | Outperform Maintained | 18 Feb 2025 |
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 36%upside $225 | Buy Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 3 articles about ASND published over the past 30 days
Negative
Zacks Investment Research
3 days ago
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Positive
Seeking Alpha
4 days ago
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launch with long runway to maximize peak sales potential. Management is wisely focusing on applying TransCon technology to rare disease markets while partnering out applications in other areas such as obesity.
Neutral
GlobeNewsWire
2 weeks ago
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
— Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years of open-label extension data — MAA in EU on track for submission during Q3 2025 COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the treatment of children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.
Positive
Zacks Investment Research
1 month ago
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
Positive
Benzinga
2 months ago
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Neutral
Seeking Alpha
2 months ago
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call.
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results.
Charts implemented using Lightweight Charts™